Methods for Identifying Analgesic Agents
AssigneeXenon Pharmaceutical Inc.
InventorsMarcia MacDonald, Mark Samuels, Robin Sherrington, Yigal Paul Goldberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of using compounds small organic compounds to treat pain as well as to predict the effect of analgesic agents in patients, such as those possessing gain of function mutations.
Claims11
A method of treating pain in a patient having a gain of function nucleotide polymorphism in an SCN9A gene, comprising administering to said patient a sodium channel blocking agent that selectively inhibits SCN9A polypeptide.
A method of predicting the analgesic effect of a sodium channel blocking agent that selectively inhibits SCN9A polypeptide in a mammal, comprising:
- (a) determining in said mammal the presence of a gain of function polymorphismin an SCN9A gene of said mammal,
- (b) administering to said mammal an effective amount of Compound A, and
- (c) determining a positive analgesic effect in said mammal due to said administering of step (b),
- wherein said positive analgesic effect in step (c) indicates a positive analgesic effect by said sodium channel blocking agent.
Dependencies are inferred from the claim text.